Filtered Listing Testing
BrightFocus President and CEO Stacy Pagos Haller spoke with WebMD about the latest breakthroughs in macular degeneration research.
Learn more about the biological hallmarks of Alzheimer’s disease.
A new study asks the question: what if we could reverse the damage caused by Alzheimer’s disease-related proteins like tau? Learn more.
Newly released research portfolios highlight the 276 biomedical research projects funded by BrightFocus Foundation across 16 countries to defeat Alzheimer’s disease, macular degeneration, and glaucoma.
The anti-amyloid therapy will go off the market later this year.
In This Issue:
- Current Research: Could Vision Lost to Glaucoma Be Restored?
- President’s Corner
- A BrightFocus Glaucoma Chat with Dr. Nazlee Zebardast
- First Look at Upcoming Research
- And more!
In this Issue
- President’s Corner
- New Blood Test Detects Unique Biomarker for Alzheimer’s
- Researcher Spotlight: Kevin Beier, PhD
- Medications That Can Mimic Dementia
- Help Fight Alzheimer’s Through a Donor Advised Fund
January is Glaucoma Awareness Month, and BrightFocus Foundation is pleased to announce the 2024 schedule of Glaucoma Chats, free, accessible and interactive audio podcast conversations with leading glaucoma specialists and eye care professionals.
A BrightFocus-funded study identifies a new player that is critical to help prevent a buildup of waste in the eye that could lead to macular degeneration.
The U.S. Food and Drug Administration has approved a new treatment for glaucoma, iDose® TR (travoprost intracameral implant, 75 mcg). iDose TR is a first-of-its kind treatment that is designed to provide up to three years of 24/7, continuous drug therapy directly inside the eye, helping people with glaucoma take control over the elevated eye pressure associated with this vision disease.